5029W-10: AUY922

CRC 10097: Phase Ib with Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer

Type of Study
Cancer (Oncology) - Colorectal
Swedish Cancer Institute
Short Description

Purpose: The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.


Open to Enrollment
Principal Investigator
Philip Gold, M.D.
Eligibility Notes
  • Histologically or cytologically confirmed colorectal cancer
  • KRAS wild type metastatic colorectal cancer
  • Progression of disease on at least 2 prior therapy to have included 5FU, or oxaliplatin or bevacizumab or irinotecan
  • Prior treatment with cetuximab is allowed (full dose tolerated), provided that the patient never required a dose reduction due to toxicities
  • Must have at least one measurable lesion
  • No prior treatment with any Hsp90 inhibitor compounds
  • No patients who received systemic anti-cancer treatment prior to the first dose of AUY922 within the following time frames:
    • Radiotherapy, conventional chemotherapy: within 2 weeks
    • Palliative radiotherapy: within 2 weeks
    • Nitrosoureas, monoclonal antibodies, such as trastuzumab and mitomycin: within 6 weeks
    • Any continuous-dosing (i.e. daily dosing, every-other-day dosing, Monday-Wednesday-Friday dosing, weekly etc.) of systemic anti-cancer treatment for which the recover period is not known, or investigational drugs (i.e. targeted agents) within a duration of ≤ 5 half lives of the agent and their active metabolites (if any)
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086